SpringWorks Therapeutics Company Insiders
| SWTX Stock | USD 49.89 1.19 2.33% |
Slightly above 84 percent of SpringWorks Therapeutics' insiders are selling. The analysis of the overall insider sentiment regarding SpringWorks Therapeutics suggests that a fairly large number of insiders are terrified. SpringWorks Therapeutics employs about 368 people. The company is managed by 12 executives with a total tenure of roughly 859 years, averaging almost 71.0 years of service per executive, having 30.67 employees per reported executive.
Insider Sentiment 16
Mostly Selling
Selling | Buying |
Latest Trades
| 2025-03-03 | Saqib Islam | Disposed 49000 @ 54.24 | View | ||
| 2025-02-20 | Saqib Islam | Disposed 29328 @ 60.3 | View | ||
| 2025-02-14 | Saqib Islam | Disposed 10672 @ 59.92 | View | ||
| 2025-02-10 | Saqib Islam | Disposed 48000 @ 53.3 | View | ||
| 2025-01-29 | Gilbert Ray Cisneros, Jr. | Acquired @ 36.52 | |||
| 2024-12-03 | Badreddin Edris | Disposed 20000 @ 41.97 | View |
Monitoring SpringWorks Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of SpringWorks Therapeutics' insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of SpringWorks Therapeutics. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe SpringWorks Therapeutics' stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
SpringWorks |
SpringWorks Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with SpringWorks Therapeutics' future performance. Based on our forecasts, it is anticipated that SpringWorks will maintain a workforce of slightly above 370 employees by April 2025.SpringWorks Therapeutics' latest congressional trading
Congressional trading in companies like SpringWorks Therapeutics, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in SpringWorks Therapeutics by those in governmental positions are based on the same information available to the general public.
| 2025-02-12 | Representative Gil Cisneros | Acquired Under $15K | Verify | ||
| 2024-08-15 | Representative Josh Gottheimer | Acquired Under $15K | Verify |
SpringWorks Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2648) % which means that it has lost $0.2648 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4662) %, meaning that it created substantial loss on money invested by shareholders. SpringWorks Therapeutics' management efficiency ratios could be used to measure how well SpringWorks Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.47 in 2025. Return On Capital Employed is likely to drop to -0.6 in 2025. At this time, SpringWorks Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 16.8 M in 2025, whereas Other Assets are likely to drop slightly above 2.2 M in 2025.Common Stock Shares Outstanding is likely to drop to about 53.5 M in 2025. Net Loss is likely to rise to about (237.2 M) in 2025
SpringWorks Therapeutics Workforce Comparison
SpringWorks Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 5,690. SpringWorks Therapeutics holds roughly 368 in number of employees claiming about 6% of equities under Health Care industry.
SpringWorks Therapeutics Profit Margins
The company has Profit Margin (PM) of (1.35) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.32) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.32.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.7 | 0.9345 |
|
|
SpringWorks Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific SpringWorks Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on SpringWorks Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, SpringWorks Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-03-01 | 0.4 | 22 | 55 | 753,234 | 650,075 |
| 2024-09-01 | 0.25 | 2 | 8 | 39,408 | 71,560 |
| 2024-06-01 | 0.7692 | 10 | 13 | 81,555 | 75,472 |
| 2024-03-01 | 0.7333 | 22 | 30 | 1,146,995 | 149,673 |
| 2023-06-01 | 7.0 | 14 | 2 | 121,972 | 3,775 |
| 2023-03-01 | 1.3158 | 25 | 19 | 1,534,146 | 1,785,330 |
| 2022-12-01 | 0.3333 | 1 | 3 | 100,000 | 111,568 |
| 2022-09-01 | 0.1429 | 1 | 7 | 30,160 | 502,687 |
| 2022-06-01 | 7.5 | 15 | 2 | 164,911 | 4,136 |
| 2022-03-01 | 1.2857 | 18 | 14 | 848,518 | 25,121 |
| 2021-12-01 | 0.2 | 1 | 5 | 10,000 | 82,500 |
| 2021-09-01 | 0.25 | 2 | 8 | 12,320 | 1,132,779 |
| 2021-06-01 | 1.0625 | 17 | 16 | 415,624 | 245,541 |
| 2021-03-01 | 2.25 | 18 | 8 | 835,525 | 2,784,500 |
| 2019-09-01 | 0.6111 | 22 | 36 | 31,431,530 | 61,642,905 |
| 2011-12-01 | 1.0 | 8 | 8 | 32,000 | 1,509,401 |
| 2010-03-01 | 0.5 | 1 | 2 | 20,000 | 40,000 |
| 2009-03-01 | 2.0 | 2 | 1 | 40,000 | 10,000 |
| 2004-03-01 | 1.0 | 2 | 2 | 200,000 | 3,525,502 |
SpringWorks Therapeutics Notable Stakeholders
A SpringWorks Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as SpringWorks Therapeutics often face trade-offs trying to please all of them. SpringWorks Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting SpringWorks Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Badreddin Edris | Chief Officer | Profile | |
| Mary Smith | Chief Officer | Profile | |
| Kim Diamond | Vice Relations | Profile | |
| James MD | Chief Officer | Profile | |
| Michael Nofi | Chief Officer | Profile | |
| TaiAn Lin | Chief Officer | Profile | |
| Saqib JD | CEO Director | Profile | |
| MBA Perier | Chief Officer | Profile | |
| Bhavesh MBA | Chief Officer | Profile | |
| Bhavesh Ashar | Chief Officer | Profile | |
| Herschel JD | General Secretary | Profile | |
| Daniel Pichl | Chief Officer | Profile |
About SpringWorks Therapeutics Management Performance
The success or failure of an entity such as SpringWorks Therapeutics often depends on how effective the management is. SpringWorks Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of SpringWorks management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the SpringWorks management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.45) | (0.47) | |
| Return On Capital Employed | (0.57) | (0.60) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (0.54) | (0.51) |
Please note, the imprecision that can be found in SpringWorks Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of SpringWorks Therapeutics. Check SpringWorks Therapeutics' Beneish M Score to see the likelihood of SpringWorks Therapeutics' management manipulating its earnings.
SpringWorks Therapeutics Workforce Analysis
Traditionally, organizations such as SpringWorks Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare SpringWorks Therapeutics within its industry.SpringWorks Therapeutics Manpower Efficiency
Return on SpringWorks Therapeutics Manpower
| Revenue Per Employee | 520.6K | |
| Revenue Per Executive | 16M | |
| Net Loss Per Employee | 701.4K | |
| Net Loss Per Executive | 21.5M | |
| Working Capital Per Employee | 762.2K | |
| Working Capital Per Executive | 23.4M |
Additional Tools for SpringWorks Stock Analysis
When running SpringWorks Therapeutics' price analysis, check to measure SpringWorks Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpringWorks Therapeutics is operating at the current time. Most of SpringWorks Therapeutics' value examination focuses on studying past and present price action to predict the probability of SpringWorks Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpringWorks Therapeutics' price. Additionally, you may evaluate how the addition of SpringWorks Therapeutics to your portfolios can decrease your overall portfolio volatility.